For PhenomeX (Nasdaq: CELL), 2023 has been a wild ride. Following the merger of Berkeley Lights and IsoPlexis on March 21, 2023, PhenomeX was formed. As a result of this merger, The Beacon Optofluidic System by Berkeley Lights and The Protein Barcoding Suite by IsoPlexis were brought together. The combination of these tools brings together two key technologies—optofluidics, which refers to the process of moving cells without physical contact, and proteomic barcoding, which evaluates the functional phenotypes of individual cells—to expand the range of possibilities for functional biology experiments..

对于PhenomeX（纳斯达克股票代码：CELL），2023年一直是狂野骑行。在2023年3月21日Berkeley Lights和IsoPlexis合并后，PhenomeX成立。合并的结果是，伯克利公司的Beacon Optofluidic System和IsoPlexis公司的Protein Barcoding Suite汇集在一起​​。这些工具的组合汇集了两种关键技术-光流体学，即没有物理接触的细胞移动过程，以及蛋白质组条形码，它评估单个细胞的功能表型，以扩大功能生物学实验的可能性范围。。

A little over four and a half months later, on August 17, 2023, PhenomeX and Bruker entered into a merger agreement. On August 31, 2023, Bruker filed with the United States Securities and Exchange Commission (also known as the “SEC”) a tender offer statement.

四个半月后，2023年8月17日，PhenomeX和布鲁克签订了合并协议。2023年8月31日，布鲁克向美国证券交易委员会（也称为“SEC”）提交了一份投标声明。

“This acquisition will mark Bruker’s entry into single-cell biology research tools, which complements Bruker’s emerging spatial biology business—in support of our transformational Project Accelerate 2.0 strategy,” said Mark R. Munch, PhD, president of the Bruker NANO Group.

布鲁克纳米集团总裁马克·R·蒙奇博士说：“这次收购将标志布鲁克进入单细胞生物学研究工具，这是对布鲁克新兴空间生物学业务的补充，以支持我们的转型项目Accelerate 2.0战略。”。

The most recent piece of information was disclosed on September 5 by PhenomeX, which stated that the Bruker Corporation has initiated, through its wholly owned subsidiary, Bird Mergersub Corporation, a cash tender offer to purchase all outstanding shares of common stock of PhenomeX for $1.00 per share.

PhenomeX于9月5日披露了最新信息，该公司表示，布鲁克公司已通过其合资子公司Bird Mergersub Corporation发起现金投标，以1.00美元的价格购买PhenomeX普通股的所有已发行股份。股份。

Following the successful completion of the tender offer, Bird Mergersub Corporation will be merged into PhenomeX, which will then become a wholly-owned subsidiary of Bruker. After the proposed acquisition, it is anticipated that the total equity value of PhenomeX will be somewhere in the vicinity of $108 million, which is a downtick from Berkeley Light’s initial public offering (IPO) in July 2020 that was set to raise at least $153 million in gross proceeds..

在成功完成投标之后，Bird Mergersub公司将合并为PhenomeX，然后PhenomeX将成为布鲁克的合资子公司。预计收购后，PhenomeX的总股权价值将在1.08亿美元左右，这是Berkeley Light在2020年7月首次公开发行（IPO）的下跌，预计将筹集至少1.53亿美元总收益。。

“By joining forces with Bruker, a respected and innovative global leader in life science research tools, we will not only enhance PhenomeX’s differentiated, high-value technologies but also our customers’ abilities to discover novel antibodies and accelerate development and manufacturing of cell and gene therapies,” said Siddhartha Kadia, PhD, CEO and director of PhenomeX..

“通过与生命科学研究工具领域备受尊敬和创新的全球领导者布鲁克合作，我们不仅将提高PhenomeX的差异化高价值技术，还将提高客户发现新型抗体，加速细胞和基因开发和制造的能力。”PhenomeX首席执行官兼首席执行官Siddhartha Kadia博士说。。

Perella Weinberg Partners served as Bruker’s financial advisor, and Morgan Lewis advised the company legally regarding the transaction, which is scheduled to be finalized during the fourth quarter of 2023. William Blair & Company, L.L.C. served as the financial advisor for PhenomeX, while Freshfields Bruckhaus Deringer LLP acted as a legal advisor..

Perella Weinberg合作伙伴担任布鲁克的财务顾问，Morgan Lewis就该交易向该公司提供法律建议，该交易将于2023年第四季度最终确定。William Blair＆Company，L.L.C。担任PhenomeX的财务顾问，而Freshfields Bruckhaus Deringer LLP担任法律顾问。。

This occurred approximately one week following the announcement of the first product resulting from the merger of IsoPlexis and Berkeley Lights. PhenomeX made public their MeteorTM chips for use on the IsoSparkTM platform on September 15, 2023. These chips were created to achieve high throughput, quantitative, fully automated, and multiplexed bulk proteomics.

这发生在IsoPlexis和Berkeley Lights合并产生的第一个产品公布后大约一周。PhenomeX于2023年9月15日公布了在IsoSparkTM平台上使用的MeteorTM芯片。创建这些芯片是为了实现高通量，定量，全自动化和多路复用的大量蛋白质组学。

The Meteor chip solution is purported to support high throughput proteomic analysis. A single full run (four chips) can accommodate 80 sample wells in triplicate, which can be quantitatively analyzed on-site. The Meteor chip will be introduced with an initial 10-plex panel, which has the extraordinary capacity to generate 2400 data points in a single run..

Meteor芯片解决方案旨在支持高通量蛋白质组学分析。一次完整运行（四个芯片）可以容纳80个样品孔，一式三份，可以在现场进行定量分析。Meteor芯片将推出最初的10-plex面板，该面板具有非凡的能力，可在一次运行中生成2400个数据点。。

PhenomeX will present Meteor at the BioProcess International 2023 meeting at the Boston Convention and Exhibition Center.

PhenomeX将在波士顿会议展览中心的BioProcess International 2023会议上展示Meteor。